Topics

Articles

cGMP line will fill vials, syringes, and cartridges, while supporting small-scale commercial production.




South Korea facility expected to provide fill-finish capabilities.




New California plant expected to streamline medicine production.




Investment expected to establish additional cGMPs, expand CDMO services. 




Joint venture expected to address pharma’s injectable drug-filling sector.





Collaboration to support biotech company’s clinical and commercial production efforts.




Plant is expected to offer packaging, serialization, and third-party contract manufacturing services.



Saint-Beauzire complex dedicated to sterile liquid drug production. 




The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

CDMO is commissioning third GMP biologics facility in Fremont.